Mauna Kea Technologies postpones release of its 2022 Half-Year Results, which was originally planned for September 22, 2022, to not later than...
Mauna Kea Technologies Postpones Release of its 2022 Half-Year Financial Results
read more
Search Results
On Target Laboratories and Mauna Kea Technologies Further Explore Targeted Detection and Real-Time Diagnosis of Lung Cancer with a Molecular Imaging Agent
Results of the 20-patient study published in the European Journal of Nuclear Medicine and Molecular Imaging demonstrated the potential for high...
Mauna Kea Technologies Announces Q2 and 1H 2022 Revenues
Stable YTD Revenue while Strategic Realignment Implemented 35% 1H U.S. Sales Growth offset by Declines in Asia Recently announced Tasly...
Tasly Pharmaceuticals and Mauna Kea Technologies Announce Joint Venture and Licensing Agreements
Mauna Kea to form Joint Venture (JV) with Tasly to develop, manufacture and commercialize Cellvizio for the Chinese market. JV also to acquire...
Mauna Kea Technologies Announces Publication of a Meta-Analysis Demonstrating Cellvizio’s Significant Role in Detection of Esophageal Dysplasia and Cancer
Results demonstrate a significant increase in the detection rate of neoplasia when Cellvizio is used as an adjunct to the standard of care,...
On Target Laboratories and Mauna Kea Technologies Demonstrate Intraprocedural Targeted Detection of Lung Cancer with a Molecular Imaging Agent
Study published in Nature Communications finds cancer-targeted molecular imaging agent with needle-based confocal laser endomicroscopy system...
Mauna Kea Technologies publishes Q1 2022 sales and its 2021 financial results
Following its 2021 restructuring, Company experiences stable U.S sales growth, including improved gross margin and anticipated reductions in...
Mauna Kea Technologies Announces First of Its Kind U.S. FDA 510(k) Clearance for Use of Cellvizio in a New Category of Molecular Imaging-guided Endoscopic, Laparoscopic, Needle-Based Procedures
Completion of a Major Regulatory Milestone for Molecular Imaging and Precision Medicine as Part of Ongoing Collaboration Mauna Kea...
On Target Laboratories and Mauna Kea Technologies Announce a Novel Clinical Research and Product Development Collaboration
The collaboration will explore and establish the value of molecular image-guided procedures for the identification and diagnosis of pulmonary...
Mauna Kea Technologies Announces Start of Enrollment in Peripheral Lung Cancer Multi-Center Clinical Trial
Study will advance the validation of Cellvizio® as a real-time biopsy guidance tool during robotic-assisted bronchoscopy that may reduce the...
Mauna Kea Technologies Announces its 2022 Financial Calendar
READ THE COMPLETE PRESS RELEASE